Heron Therapeutics, Inc. (HRTX)
Nasdaq · Healthcare · Biotechnology
$0.37+6.44%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $70.3M
- 52-week range
- $0.26 – $1.58
- 52-week change
- −73.48%
- EPS (trailing)
- −$0.18
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $155M (+7.36%)
- Net income
- −$20.0M
- Operating margin
- −1.6%
- Diluted EPS
- −$0.12
- Free cash flow
- −$27.9M
From the company’s annual report on SEC EDGAR.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Headquarters: Cary, United States · 128 employees · herontx.com